Origin
KAIST
Korea Advanced Institute of Science and Technology, Daejeon. Where the CGG Amino-Bridge approach came from, and where the early research was done.
CREGEN Scientific · Pilot data · EIMEC Barcelona
One result reached
One result reached
significance. The rest
are trends, and we
say so.
A CREGEN publication. Not a peer-reviewed journal.
A 15-day independent pilot in Barcelona measured how much creatine leaves the body. This page is what it found, including what it did not find.
30-day money-back guarantee · Free U.S. shipping over $149
From the research team
To the reader,
CREGEN did not begin in a marketing department. It began in a laboratory at KAIST, Korea's leading institute of science and technology. It began with a simple question: how much of a dose does the body actually keep?
The answer guiding the CGG Amino-Bridge was straightforward. Pair creatine monohydrate with the amino acids glycine and glutamine, and measure whether more of each dose is retained instead of passing through.
We believe performance science should be honest about its limits. The human data here comes from one small, preliminary pilot, not a finished clinical program. We report what it measured, including the results that were only directional.
Two institutions, two roles: KAIST is the origin of the early research. EIMEC ran the independent measurement.
With rigor, Dr. Jo Su-Yeon, Ph.D. Lead Researcher · CGG Amino-Bridge · KAIST
The measurement
What the pilot measured.
What the pilot measured.
And what it didn't.
EIMEC Barcelona had no part in creating CREGEN. As an independent third party they ran a bioavailability pilot comparing CREGEN against a competitor creatine.
Figure 1. Urinary creatine loss, spot urine, day 15. Independent pilot, EIMEC Barcelona. n=2-3 per group · 5 g/day · 15 days · p=0.028. The pilot's only statistically significant result. See the packs.
| Measure | Result | Significance |
|---|---|---|
| Spot urine creatine | 56% lower | Significant, p=0.028 |
| Serum creatine | +23% | Not significant, directional |
| Plasma creatine | +26% | Not significant, directional |
In a 15-day independent pilot at EIMEC Barcelona (n=2-3 per group, 5 g/day), the CREGEN group excreted 56% less creatine in spot urine than the comparator group (p=0.028). That is the only result in the pilot that reached statistical significance. Serum creatine (+23%) and plasma creatine (+26%) were directional trends that did not.
Limitations: n=2-3 per group, fifteen days, one site, exploratory. A pilot this small cannot establish an effect. It can only justify a larger study.
In plain English
Retention is a measurement,
Retention is a measurement,
not a feeling.
Creatine that leaves in your urine is creatine your muscles never had a chance to take up. That is the whole of what was measured here: how much stayed, not how anyone felt.
In practice it means one 5 g sachet a day. No loading phase, no measuring, no megadosing. You can start with a single month and decide from there.
Retention is what we measured. It is not a promise about focus, energy or how you will feel.
Two institutions
Developed in Korea.
Developed in Korea.
Measured by someone else.
Measurement
EIMEC Barcelona
An independent European institute with no part in creating the product. They ran the pilot and reported what they found, including the results that were not significant.
Dr. Jo Su-Yeon, Ph.D. Lead Researcher, CGG Amino-Bridge. B.S., M.S. and Ph.D. all earned at KAIST. Principal researcher on the formulation. Patent pending, KR-2023-0118.
Research index
The creatine literature
01
Published literature
02
Meta-analysis, 2023
03
Randomised trial, 2023
04
Formulation note
The creatine literature
this is built on.
We didn't publish any of these. We read them.
Creatine, phosphocreatine and ATP regeneration
Creatine's well-documented role in cellular energy metabolism. The background any creatine product rests on, ours included.
Creatine supplementation and memory in healthy individuals
Systematic review and meta-analysis of randomised controlled trials. Found a small improvement in memory versus placebo, larger in older adults. Dose across the trials, roughly 2.2 to 20 g a day, did not change the outcome.
Creatine and cognitive performance, randomised controlled study
The largest trial to date, 123 participants, cross-over and double-blind, at 5 g a day for six weeks. Reported a small beneficial effect and called for larger studies.
Single-sachet dosing and gastrointestinal tolerability
Formulation rationale for a one-sachet daily protocol rather than a high-dose loading routine. Available on request.
- Prokopidis K, et al. Nutrition Reviews 2023;81(4):416-427. doi:10.1093/nutrit/nuac064
- Sandkühler JF, et al. BMC Medicine 2023;21:440. doi:10.1186/s12916-023-03146-5
- CREGEN pilot: EIMEC Barcelona, n=2-3 per group, 5 g/day, 15 days. Preliminary and exploratory. Summary available on request.
The full summary
Want the pilot write-up?
We will send the EIMEC pilot summary, methods and all, including the results that did not reach significance. No newsletter attached.
Request the summary →
Before you buy
The questions we
The questions we
actually get asked.
What is the difference between KAIST and EIMEC?
KAIST, the Korea Advanced Institute of Science and Technology, is where
the early research behind the CGG Amino-Bridge originated. EIMEC Barcelona is an
independent European institute that had no part in creating the product and ran the
pilot that measured it. Origin and measurement, deliberately kept separate.
How is CREGEN different from regular creatine monohydrate?
CREGEN is creatine monohydrate paired with glycine and glutamine, taken
as one 5 g sachet a day. In the EIMEC pilot the CREGEN group had 56% less creatine in a spot urine sample
than the comparator (n=2-3 per group, p=0.028). Monohydrate on its own is
effective, well studied and cheaper, and we are not going to pretend otherwise.
Do I need a loading phase?
No. One sachet a day, every day, for as long as you want the benefit.
No loading, no cycling, no kitchen scale.
Will it upset my stomach?
The pilot reported zero adverse events over fifteen days, in a group of
two to three people. That is too small a sample to make a claim about tolerability, so
we will not make one. What we can say is that CREGEN is a single 5 g sachet rather than
the high-dose routines that are the usual source of complaints.
When will I notice a difference?
Individual results vary, and we have not measured a subjective endpoint
of any kind. Creatine works on the timescale of weeks and months, not days, which is
why the 90-day protocol is the one most people choose. Every order is backed by a
30-day money-back guarantee.
Is it made in China?
No. The CGG technology was researched and developed in South Korea at
KAIST, and the product is manufactured in South Korea under GMP certification and
third-party tested for purity and potency.
How do you back up what is on this page?
Every figure here comes from the independent EIMEC pilot or from the
published creatine literature listed in the research index above, with its DOI. Where a
result did not reach significance, we say so in the same sentence as the number.
The protocol
Creatine works on the timescale
Creatine works on the timescale
of months, not days.
Which is why the 90-day protocol is the one most people choose. One sachet of 5 g a day, backed by a 30-day money-back guarantee.
CREGEN Scientific is published by Nuderma Group LLC, Miami, and is not a peer-reviewed journal. Figures come from an independent pilot at EIMEC Barcelona (n=2-3 per group, 5 g/day, 15 days, preliminary and exploratory) and from the published literature cited above. Where a result did not reach statistical significance, it is labelled as a directional trend. Last reviewed 21 September 2026.